Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: A multicentre study of 12 patients
Australasian Journal of Dermatology · 2024
DOI: 10.1111/ajd.14264 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Australasian Journal of Dermatology, 2024. Verfasst von Francisco José Navarro-Triviño und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Contact Eczema and Immunoallergic Diseases, Dermatology Department, Hospital Universitario San Cecilio, Granada, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Quality of Life. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Abstract (Originalsprache)
Background/Objectives The evaluation of the efficacy and safety of new molecules for atopic dermatitis (AD) in real clinical practice is very important to obtain information that clinical trials (EECC) lack. The pattern of AD in the head and neck (H&N) continues to be a challenge in treatment today, despite the new molecules, and real‐life data on the use of tralokinumab is still missing. This is the first daily practice study of tralokinumab treatment in patients with H&N AD pattern. The objective is to evaluate the efficacy and safety of tralokinumab in the short term (16 weeks) in patients with AD with H&N pattern, for the first time.
Methods
A multicentre prospective observational study was conducted, including patients with moderate‐severe AD and H&N pattern who started tralokinumab treatment in four hospitals in Andalusia. Values of severity and quality of life scales, as well as patient‐reported outcomes (PROs), were collected at baseline and at Weeks 4 and 16. Safety events were also recorded.
Results
Twelve patients were included. An improvement was observed in all efficacy and quality of life parameters evaluated at 16 weeks with respect to the baseline. No serious adverse events were recorded.
Conclusions
In real clinical practice, tralokinumab is demonstrated to be an effective and safe treatment for patients with AD and H&N pattern at short term.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Contact Eczema and Immunoallergic Diseases, Dermatology Department, Hospital Universitario San Cecilio, Granada, Spain.
- Instituto de Investigación Biosanitaria de Granada, Granada, Spain.
- Department of Dermatology, Hospital Universitario Virgen de las Nieves, Granada, Spain.
- Department of Dermatology, Hospital Universitario Reina Sofía, Córdoba, Spain.
- Instituto Maimonides de Investigación Biomédica de Córdoba, Córdoba, Spain.
- Department of Dermatology, Hospital Universitario Poniente en El Ejido, Almería, Spain.
ORCID-Profile: Francisco José Navarro-Triviño, Cintia Arjona-Aguilera
Zitieren
APA
Navarro-Triviño, F. J., Salazar-Nievas, M., Sanz-Cabanillas, J. L., & Arjona-Aguilera, C. (2024). Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: A multicentre study of 12 patients. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14264
Vancouver
Navarro-Triviño FJ, Salazar-Nievas M, Sanz-Cabanillas JL, Arjona-Aguilera C. Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: A multicentre study of 12 patients. Australasian Journal of Dermatology. 2024. doi:10.1111/ajd.14264
BibTeX
@article{NavarroTrivio2024,
author = {Navarro-Triviño, Francisco José and Salazar-Nievas, María and Sanz-Cabanillas, Juan Luis and Arjona-Aguilera, Cintia},
title = {Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: A multicentre study of 12 patients},
journal = {Australasian Journal of Dermatology},
year = {2024},
doi = {10.1111/ajd.14264}
}
EUVIMED